Open an Account
Open an Account

FX Week Ahead 20.07.20

FX Week Ahead 20.07.20

FX Week Ahead 20.07.20

in Weekly Market Brief

Positive vaccine news boosted risk sentiment this week from Moderna and the Astrazeneca Oxford led group. Moderna’s vaccine trial produced a strong immune response for all 46 patients in an early stage human trial and the findings show the vaccine could provide protection against the coronavirus. Alongside the vaccine news the hopes of further Fed stimulus supported the risk on tone as the S&P500 tested June’s highs. Will optimistic medical news keep on supporting stocks next week or will signs of a slowing global economy weigh on investor sentiment?

Key events from the past week

  • CAD: Interest rate decision, July 15. The Bank of Canada kept rates unchanged and stated that it does not expect the economy to return to pre-covid19 levels until 2022. They also kept asset purchases unchanged. The BoC underlined the uncertainty facing the Canadian economy.
  • Oil: OPEC+ meeting, July 15. The OPEC+ panel agreed in principle to tapering production cuts in August according to delegates. The concern now going forward is that the oil market will be overwhelmed with extra supply from these cuts. Will these bring oil prices lower from here technically capped by the 200DMA?
  • EUR: Interest rate decision, Thursday July 16. The ECB left rates and PEPP purchases unchanged at their latest decision. However, hopes for fiscal unity surrounding a European Union rescue package has driven EUR demand this week.

Key events for the coming week

  • EUR: German manufacturing PMI’s, July 24. The PMI data from Germany is starting to show signs of bottoming. Will Friday’s data reassure markets that some kind of recovery is still on the way? Or will falls below 40 reveal deeper problems for Europe’s largest contributor?
  • EUR: European Recovery Fund, July 17/18. On Friday and Saturday EU policy makers will meet to discuss the €750 billion recovery plan.The main issue is whether nations like Austria, Denmark, Sweden, Netherland and Finland will block the plan. If they do block it expect EUR sellers on Sunday’s open.
  • Vaccine hopes to stimulate stocks? Will the positive vaccine news from this week lead to a strong run higher in global stocks or will weak earnings next week drag them down?

Latest Posts

11/12/2020
Week Ahead 14.11.20
23/02/2023
Fed focus
17/11/2022
UK inflation surge
20/11/2020
Week Ahead 23.11.20

HYCM Lab is a financial analysis source that provides regular insights on how global news affects the markets including forex, commodities, stocks, indices, and cryptocurrencies*. Run by the HYCM team, it equips traders with everything needed to make informed trading decisions.

Legal Forms & Documents      |      Risk Warnings      |      Cookies Policy

Disclaimer: Any opinions made may be personal to the author and may not reflect the opinions of HYCM. All expressions of opinion are subject to change without notice. This material is considered a marketing communication and does not contain, and should not be construed as containing, investment advice or an investment recommendation or, an offer of or solicitation for any transactions in financial instruments. HYCM makes no representation and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied by an employee of HYCM, a third party or otherwise. Past performance is not an indication of possible future performance. Without the approval of HYCM, reproduction or redistribution of this information isn’t permitted.

Legal Information: HYCM is the trading name of HYCM Capital Markets (UK) Limited, HYCM (Europe) Ltd, HYCM Limited and HYCM Capital Markets (DIFC) Limited for which the HYCM Capital Markets group is holding company and its assets are a controlling equity interest in them.​

High-Risk Investment Warning: Contracts for Difference (‘CFDs’) are complex financial products that are traded on margin. Trading CFDs carries a high degree of risk. It is possible to lose all your capital. These products may not be suitable for everyone and you should ensure that you understand the risks involved. Seek independent expert advice if necessary and speculate only with funds that you can afford to lose. Please think carefully whether such trading suits you, taking into consideration all the relevant circumstances as well as your personal resources. We do not recommend clients posting their entire account balance to meet margin requirements. Clients can minimise their level of exposure by requesting a change in leverage limit. For more information please refer to HYCM’s Risk Disclosure.

*Cryptocurrencies are not available for trading under HYCM (Europe) Limited and HYCM Capital Markets (UK) Limited (retail clients only).

*Other fees may apply, such as withdrawal fees, dormant account fees, swaps, and spreads.

*Certain products & services mentioned herein may or may not be available to all clients depending on which HYCM Capital Markets Group entity their trading account(s) adheres to.

*Any opinions made in this material are personal to the author and do not reflect the opinions of HYCM. This material is considered a marketing communication and should not be construed as containing investment advice or an investment recommendation, or an offer of or solicitation for any transactions in financial instruments. Past performance is not a guarantee of or prediction of future performance. HYCM does not take into account your personal investment objectives or financial situation. HYCM makes no representation and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast, or other information supplied by an employee of HYCM, a third party or otherwise.

Copyright © 2023 HYCM

Legal Forms & Documents

Risk Warnings

Cookies Policy

Disclaimer: Any opinions made may be personal to the author and may not reflect the opinions of HYCM. All expressions of opinion are subject to change without notice. This material is considered a marketing communication and does not contain, and should not be construed as containing, investment advice or an investment recommendation or, an offer of or solicitation for any transactions in financial instruments. HYCM makes no representation and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied by an employee of HYCM, a third party or otherwise. Past performance is not an indication of possible future performance. Without the approval of HYCM, reproduction or redistribution of this information isn’t permitted.

Legal Information: HYCM is the trading name of Henyep Capital Markets (UK) Limited, HYCM (Europe) Ltd, HYCM Limited and Henyep Capital Markets (DIFC) Limited for which the Henyep Capital Markets group is holding company and its assets are a controlling equity interest in them.

* Cryptocurrencies are not available for trading under HYCM (Europe) Limited and Henyep Capital Markets (UK) Limited (retail clients only).

*Any opinions made in this material are personal to the author and do not reflect the opinions of HYCM. This material is considered a marketing communication and should not be construed as containing investment advice or an investment recommendation, or an offer of or solicitation for any transactions in financial instruments. Past performance is not a guarantee of or prediction of future performance. HYCM does not take into account your personal investment objectives or financial situation. HYCM makes no representation and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast, or other information supplied by an employee of HYCM, a third party or otherwise.

Copyright © 2023 HYCM